COMMUNIQUÉS West-GlobeNewswire

Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions
13/08/2025
BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the Phase 1a trial in aged human subjects of its NNI-362 therapy was [...]
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC’s 2025 [...]
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
13/08/2025
Denali’s registration statement on Form S-4 declared effective by the Securities and Exchange Commission Extraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the proposed business [...]
LIO Launches Next-Generation Inpatient Mental Health Platform with Advanced Rounding, Monitoring, and Compliance Tools
13/08/2025
The platform’s capabilities will support frontline staff and facility leaders, and promote patient safety WILMINGTON, Del., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIO today announced the launch of its new all-in-one platform [...]
Corza Medical Launches Biomedical Textiles Innovation Lab to Accelerate OEM Product Development
13/08/2025
TAUNTON, U.K., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global manufacturer of surgical technologies and medical device components announced today the launch of its Biomedical Textiles Innovation Lab, [...]
Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity
13/08/2025
This is the first ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune disease The Phase 1/2 study (up to 141 participants) will evaluate the [...]
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
13/08/2025
Pratteln, Switzerland , 13 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion [...]
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
13/08/2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat [...]

Pages